Accelerated Corneal Crosslinking for Treatment of Progressive Keratoconus in Pediatric Patients
| Autor: | Mustafa Ataş, Ayşe Özköse, Gokmen Zararsiz, İsa Yuvacı, Döndü Melek Ulusoy, Hasan Basri Arifoglu, Emre Göktaş, Necati Duru |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
0301 basic medicine medicine.medical_specialty Keratoconus Visual acuity Adolescent genetic structures Visual Acuity Corneal Transplantation Young Adult 03 medical and health sciences 0302 clinical medicine Ophthalmology medicine Humans In patient Young adult Child Photosensitizing Agents medicine.diagnostic_test business.industry Disease progression Corneal Topography General Medicine medicine.disease Corneal topography eye diseases Surgery Cross-Linking Reagents Cross-Sectional Studies 030104 developmental biology Photochemotherapy Disease Progression 030221 ophthalmology & optometry Female Collagen medicine.symptom business |
| Zdroj: | European Journal of Ophthalmology. 27:319-325 |
| ISSN: | 1724-6016 1120-6721 |
| Popis: | Purpose To evaluate the safety and efficacy of accelerated corneal crosslinking (CXL) in patients with progressive keratoconus aged 18 years or less. Methods A total of 28 eyes from 19 patients with progressive keratoconus aged 18 years or less were enrolled. We divided participants into 2 groups according to corneal thickness (CT). Group 1 included 13 eyes of 8 patients with CT ≥450 µm; group 2 included 15 eyes of 11 patients with CT 2 for a total energy dose of 5.4 J/cm2. The efficacy and safety of the procedure were assessed postoperatively at 1, 3, 6, and 12 months with Pentacam and visual acuity. Results In uncorrected visual acuity, group 1 showed a statistically significant +0.12 logMAR improvement at 3 months postoperatively (p = 0.003), and in group 2, there was a statistically significant +0.3 logMAR improvement at 1 month postoperatively (p = 0.005). In best-corrected visual acuity, there was a +0.15 logMAR (pConclusions The findings showed that accelerated CXL treatment seems to be effective in slowing or halting the progression of keratoconus and that no permanent apparent complications are noted 6 months after accelerated CXL. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|